Epigenetic-Modifying Agents Show Potential in Treating Radioablation-Resistant Thyroid Cancer

Strategic Insights -

Epigenetic-modifying agents, specifically sodium butyrate and decitabine (5-Aza-dC), have shown promise in increasing iodine uptake in thyroid carcinoma cells, potentially leading to more effective treatment options for radioablation-resistant thyroid cancer. Researchers at the University of Iowa, led by M.J. Provenzano, conducted a study to investigate the effect of these agents on human thyroid carcinoma cell lines. Their findings, published in the journal Otolaryngology - Head and Neck Surgery, suggest that epigenetic-modifying agents may be a viable treatment approach for this type of cancer.

Key Takeaways:

  • The study found that human thyroid carcinoma cell lines DRO and 2-7 had high levels of DNA methylation (74% and 80%), compared to normal thyroid tissue (6%).
  • The researchers discovered that treatment with sodium butyrate and decitabine (5-Aza-dC) significantly increased iodine uptake in these cell lines.
  • The study's findings indicate that epigenetic-modifying agents, such as sodium butyrate and decitabine (5-Aza-dC), show promise in treating radioablation-resistant thyroid cancer.
  • The research has implications for the development of new therapeutic strategies for thyroid cancer, particularly for patients who do not respond to conventional treatments.
  • The study's results contribute to a deeper understanding of the epigenetic mechanisms underlying thyroid cancer and may lead to the discovery of new biomarkers for early detection and monitoring of the disease.

Statistics:

  • 74% and 80%: The levels of DNA methylation in human thyroid carcinoma cell lines DRO and 2-7, respectively.
  • 6%: The level of DNA methylation in normal thyroid tissue.
  • 5-Aza-dC: The chemical name for decitabine, an epigenetic-modifying agent used in the study.
  • 137(5): The volume and issue number of the journal Otolaryngology - Head and Neck Surgery where the study was published.
  • 722-728: The page numbers of the published study.

Sources:

  • Provenzano, M.J., et al. "Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)." Otolaryngology - Head and Neck Surgery 2007;137(5):722-8.
  • Mosby, Inc., 11830 Westline Industrial Dr., St. Louis, MO 63146-3318, USA (Publisher of Otolaryngology - Head and Neck Surgery).